Side-by-side · Research reference

DSIPvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 1Reviewed10/36 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

DSIP

GHRP-6

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

DSIP

GHRP-6

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

100–200 mcg per injectionBowers 1990

Frequency

Once daily, pre-sleep

1–3× per day

Lower / starter dose

50 mcg pre-sleep

50 mcg per dose

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 1 + clinical practiceBowers 1990

Duration

8–12 weeks per cycle

8–12 weeks on / 4 off

Reconstitution

Bacteriostatic water

Timing

30–60 min pre-sleep

Pre-meal preferred for appetite support

Half-life

Short plasma; CNS effects last hours

~15 minMalagón 1999

04Side Effects & Safety

Parameter

DSIP

GHRP-6

Injection site reaction

Mild irritation

Mild

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Cancer risk

—

Contraindicated in active malignancy

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

DSIP

GHRP-6

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Injection site

SQ — abdomen. Rotate sites.

3. Timing

30–60 min pre-sleep.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G insulin syringe.

29–31G, 4–8 mm insulin syringe.